143 related articles for article (PubMed ID: 12270445)
1. Effects of three immunosuppressive regimens on CD4 helper function, B cell monocyte and cytokine responses in renal transplant recipients: 4-month follow-up of a prospective randomized study.
Weimer R; Streller S; Staak A; Heilke M; Li D; Dietrich H; Daniel V; Feustel A; Rainer L; Zinn S; Friemann S; Ernst W; Grimm H; Padberg W; Zimmermann T; Opelz G
Transplant Proc; 2002 Sep; 34(6):2377-8. PubMed ID: 12270445
[No Abstract] [Full Text] [Related]
2. Conversion to tacrolimus immunosuppression in renal transplant recipients: 12-month follow-up.
Citterio F; Scatà MC; Romagnoli J; Pozzetto U; Nanni G; Castagneto M
Transplant Proc; 2002 Aug; 34(5):1685-6. PubMed ID: 12176535
[No Abstract] [Full Text] [Related]
3. Impaired T-cell IL-10 secretion and CD4 helper function in liver transplant patients treated with tacrolimus.
Zipperle S; Weimer R; Golling M; Daniel V; Otto G; Opelz G
Transplant Proc; 1997; 29(1-2):1079-80. PubMed ID: 9123208
[No Abstract] [Full Text] [Related]
4. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil.
Weimer R; Süsal C; Yildiz S; Streller S; Pelzl S; Staak A; Renner F; Dietrich H; Daniel V; Feuring E; Kamali-Ernst S; Ernst W; Padberg W; Opelz G
Transplant Proc; 2005 May; 37(4):1776-8. PubMed ID: 15919463
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
[TBL] [Abstract][Full Text] [Related]
6. Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response.
Weimer R; Deisz S; Dietrich H; Renner F; Bödeker RH; Daniel V; Kamali-Ernst S; Ernst W; Padberg W; Opelz G
Transpl Int; 2011 Jun; 24(6):596-609. PubMed ID: 21401729
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
[No Abstract] [Full Text] [Related]
8. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation.
Yu L; Wang Y; Fu SJ; Cheng XJ
Transplant Proc; 2000 Nov; 32(7):1709-10. PubMed ID: 11119902
[No Abstract] [Full Text] [Related]
10. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.
Teebken OE; Strüber M; Harringer W; Pichlmaier MA; Haverich A
Transplant Proc; 2002 Jun; 34(4):1265-8. PubMed ID: 12072335
[No Abstract] [Full Text] [Related]
11. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of immunosuppressive induction regimens in renal transplantation. Collaborative Transplant Study.
Opelz G
Transplant Proc; 1998 Dec; 30(8):4029-30. PubMed ID: 9865286
[No Abstract] [Full Text] [Related]
13. Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study.
Wong KM; Cheung CY; Chan YH; Chak WL; Choi KS; Chau KF; Li CS
Transplant Proc; 2000 Nov; 32(7):1721-2. PubMed ID: 11119907
[No Abstract] [Full Text] [Related]
14. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy.
Scott-Douglas N; Zimmerman D; Klassen J
Transplant Proc; 1996 Dec; 28(6):3165. PubMed ID: 8962226
[No Abstract] [Full Text] [Related]
16. Drug regimens affect cadaveric kidney graft survival.
Kauffman HM; Cherikh WS; Delmonico FL
Transplant Proc; 2001; 33(1-2):1029-30. PubMed ID: 11267176
[No Abstract] [Full Text] [Related]
17. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
[TBL] [Abstract][Full Text] [Related]
18. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
Tsai SF; Cheng CY; Shu KH; Wu MJ
Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
[TBL] [Abstract][Full Text] [Related]
19. Effect of different anti-rejection regimens on the expression of differentiation and activation markers on the surface of host lymphocytes.
Malinowski K; Ye H; Waltzer WC
Transplant Proc; 2000 Jun; 32(4):773-5. PubMed ID: 10856579
[No Abstract] [Full Text] [Related]
20. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin.
Kyo M; Ichikawa Y; Hanafusa T; Fukunishi T; Nagano S; Takahara S; Kokado Y; Okuyama A; Ihara H; Ito K; Sagawa S; Sonoda T; Akiyama T; Kurita T; Suzuki S; Amemiya H
Transplant Proc; 1996 Apr; 28(2):910-1. PubMed ID: 8623457
[No Abstract] [Full Text] [Related]
[Next] [New Search]
